Tennessee Oncology is a prominent player in the health care industry and a leading provider of community-based cancer care in the United States. Established in 1976 in Nashville, the company has a strong emphasis on providing high-quality cancer care and access to clinical research for patients within their communities. Their recent $98.30M Debt Financing investment secured on 03 July 2023 from Truist Ventures underlines their commitment to expanding their services and reach.
Tennessee Oncology's comprehensive range of services includes diagnostic services, in-house chemotherapy treatments, and the use of molecular diagnostics for personalized treatment plans based on the genetics of the patient's cancer. Furthermore, the company operates an in-house pharmacy, Park Pharmacy, that offers a wide range of specialty medications and patient support services, including insurance and benefits investigation, prior authorization, and round-the-clock access to pharmacists.
As a founding partner of OneOncology, Tennessee Oncology is driving the future of community-based cancer care in the U.S. with its expanding network of physicians and convenient clinic locations. With a focus on gynecologic oncology, palliative care, radiation oncology, and health psychology, the company is well-positioned to meet the diverse needs of cancer patients. Through its participation in oncology research and clinical trials, Tennessee Oncology demonstrates a commitment to advancing treatments and improving patient outcomes in the fight against cancer.
With its mission to provide accessible and top-quality cancer care, Tennessee Oncology continues to make a significant impact in the field of oncology and holds great potential for continued growth and innovation in the years to come.
No recent news or press coverage available for Tennessee Oncology.